Preparation method and application of exosome ferulic acid nanocomposite

Abstract

The invention belongs to the technical field of biological carriers, and particularly relates to a preparation method and application of an exosome ferulic acid nano-composite. The invention provides a way for preparing ferulic acid nano-particles by using exosomes, and particularly relates to a preparation process for forming a nano-composite by using ferulic acid and stress yeast exosomes generated by stimulation. The preparation method of the exosome ferulic acid nano-composite provided by the invention has the advantages of high safety, low immunological rejection, high cell fusion degree, high entrapment rate and good stability. Besides, the selected stress yeast exosome can effectively protect and enhance the anti-inflammatory and anti-oxidation effects of ferulic acid, so that the prepared exosome ferulic acid nano-composite has relatively strong anti-inflammatory, anti-oxidation and repair effects, and has a good application prospect in the field of cosmetics or medicines.

Description

Technical Field

[0001] The present invention belongs to the technical field of biological carriers, and specifically relates to a preparation method of an exosome ferulic acid nanocomposite and an application thereof. Background Art

[0002] Ferulic acid (FA) is a phenolic acid extracted from plant species, such as Ferula, Angelica, Chuanxiong, Cimicifuga, etc., and is also one of the main active ingredients of these Chinese herbal medicines. Ferulic acid is mainly present in the cell wall of plants, mostly in the form of chemical combination, and is a cinnamic acid type phenolic acid, which is one of the derivatives of cinnamic acid. Ferulic acid has a wide range of pharmacological effects and is clinically used to treat diseases such as hypertension, coronary heart disease, thromboangiitis, acute cerebral thrombosis, migraine and atherosclerosis. With the in-depth research in recent years, it is found that ferulic acid also has many new pharmacological effects, such as inhibiting tyrosinase activity, absorbing ultraviolet rays, anti-oxidation, scavenging free radicals, delaying skin aging, etc. However, its solubility in water is low, its bioavailability is low, and its stability is poor under physical and thermal stress, which greatly limits the application of ferulic acid.

[0003] Exosomes refer to nanospheres produced by cells that communicate between cells and have a double-layer membrane structure. They have a diameter between 40 and 100 nm and can carry nucleic acids, proteins, lipids and enzymes. Exosomes from different sources have their own specific surface molecules and play an important role in the transmission of information between cells. Due to their small size, exosomes can reduce the clearance of the immune system and transport more drugs to the lesion site. Therefore, exosomes can be used as potential drug carriers. Compounds can be loaded into vesicle-like structures to achieve the functions of aqueous solution drug loading, increased transdermal and targeted delivery. Exosomes have been used in the packaging of compounds to achieve better transdermal and delivery effects.

[0004] Patent document CN115105494A discloses a kind of exosome-encapsulated glabridin with whitening effect, and its preparation method and application. The exosome-encapsulated glabridin is prepared by mixing the exosomes secreted by dermal fibroblasts with an alcohol solution dissolved with glabridin in a mass ratio of (1-5): (10-20). The exosome-encapsulated glabridin solves the problem that the effect of glabridin is limited in practical applications. The glabridin encapsulated by the dermal fibroblast exosomes can assist glabridin to efficiently pass through the melanocyte membrane, enhance the ability of glabridin to target melanocytes, and play a role in inhibiting melanin synthesis, thereby effectively treating diseases such as abnormal pigmentation and improving the effectiveness and utilization rate of glabridin.

[0005] Patent document CN 116392601A discloses a composite modified exosome-encapsulated resveratrol preparation and a preparation method thereof. The preparation is prepared by using milk-derived exosomes to encapsulate resveratrol, and then cholesterol-RGD modification is performed on the exosomes to obtain the preparation, so that the prepared composite modified exosome-encapsulated resveratrol preparation has the advantages of strong availability, low cost, low toxicity, high yield, and suitability for large-scale production. The bioavailability of encapsulated resveratrol is enhanced by cholesterol-RGD modification of milk-derived exosomes, and the efficacy of resveratrol can also be improved.

[0006] Considering that the commonly used carrier technologies for ferulic acid, such as phospholipid complexes, nanoemulsions, cyclodextrin inclusion complexes, hydrogels, and molecular cages, all have certain defects, including low encapsulation rate, low stability, decreased anti-inflammatory and antioxidant effects after encapsulation, and immune rejection, etc. Therefore, researching and developing a ferulic acid encapsulation process with high biocompatibility, high encapsulation rate, and high antioxidant and anti-inflammatory effects is a problem that needs to be solved urgently. Summary of the invention

[0007] In order to solve the defects of the prior art, the present invention provides a method for preparing ferulic acid nanoparticles using exosomes, especially a method for preparing a nanocomposite formed by stimulating stressed yeast exosomes and ferulic acid. The object of the present invention is to provide a method for preparing an exosome ferulic acid nanocomposite, especially using stress-induced yeast exosomes to prepare an exosome ferulic acid nanocomposite with high biocompatibility, high encapsulation rate, and high antioxidant and anti-inflammatory effects. Another object of the present invention is to provide an application of an exosome ferulic acid nanocomposite in the preparation of cosmetics or medicines.

[0008] The present invention provides a method for preparing an exosome ferulic acid nanocomposite, comprising the following steps:

[0009] Step S1. Add yeast-derived exosomes to a phosphate buffered saline solution and resuspend the exosomes so that the mass percentage of the exosomes in the suspension is 0.05-0.12%, thereby obtaining a yeast-derived exosome solution; the concentration of the phosphate buffered saline solution is 0.01 mol / L;

[0010] Step S2. adding ferulic acid to an ethanol solution having a volume concentration of 75 to 95%, stirring uniformly to obtain a ferulic acid solution;

[0011] Step S3. The yeast-derived exosome solution obtained in step S1 and the ferulic acid alcohol solution obtained in step S2 are mixed evenly to obtain a mixed solution, and the mixed solution is subjected to ultrasonic treatment under ice bath conditions, and then allowed to stand at a temperature of 20 to 37° C. for 60 to 100 minutes, centrifuged, and the supernatant is obtained.

[0012] Furthermore, the method for preparing yeast-derived exosomes in step S1 is:

[0013] Step A, taking the activated Pichia pastoris plate bacteria, inoculating it into a conical flask filled with YEPD culture medium, and culturing it in a shaking incubator at a temperature of 28° C. for 12 h to obtain a Pichia pastoris seed solution;

[0014] Step B, inoculating the Pichia pastoris seed liquid prepared in step A into a conical flask filled with fresh YEPD medium at an inoculation amount of 5%, culturing in a shaking incubator at a temperature of 28° C. to the mid-logarithmic phase, then raising the temperature in the medium to 40° C., and continuing to culture for 36 hours to reach a stable phase to obtain a fermentation liquid;

[0015] Step C, centrifuging the fermentation broth obtained in step B at a speed of 6000-7000 rpm for 8-10 minutes, collecting the supernatant, centrifuging the supernatant at a temperature of 2-8°C and 5000-8000g for 10-30 minutes, collecting the supernatant, and filtering the supernatant through a 0.2 μm sterile filter membrane to obtain a filtrate;

[0016] Step D: Centrifuge the filtrate obtained in step C at 100,000 to 120,000 g for 60 to 80 min, and discard the supernatant to obtain the product.

[0017] Furthermore, the concentration of the ferulic acid solution in step S2 is 1-10 mg / mL.

[0018] Furthermore, in step S3, the yeast-derived exosome solution and the ferulic acid solution are uniformly mixed in a mass percentage of (80-95):(5-20).

[0019] Furthermore, the conditions for ultrasonic treatment in step S3 are: under ice bath conditions, the ultrasonic power is 200-400 W, the working time is 2-10 s, the interval time is 2-34 s, the cycle is 5-40 times, and the ice bath is cooled for 3-10 minutes before ultrasonic treatment is performed again.

[0020] Furthermore, the centrifugal conditions in step S3 are: centrifugation at a temperature of 2 to 4° C. and 5000 to 10000 g for 10 to 15 min.

[0021] In addition, the present invention also claims to protect the exosome ferulic acid nanocomplex prepared by the preparation method of the exosome ferulic acid nanocomplex.

[0022] In addition, the present invention also provides the use of the exosome ferulic acid nanocomposite in the preparation of cosmetics or medicines.

[0023] Furthermore, the present invention also provides the use of the exosome ferulic acid nanocomplex in the preparation of repairing antioxidant cosmetics.

[0024] At present, in order to improve the water solubility and stability of ferulic acid, the inventors have consulted a large number of literature and materials, and for the first time tried to use exosomes to load ferulic acid to improve its performance. However, it was found through experiments that the encapsulation rate of ferulic acid by exosomes secreted by dermal fibroblasts and plant exosomes did not reach the expected effect. After continuous exploration and research, the inventors found that when Pichia pastoris encounters high temperature stress, the yeast cells produce a stress response and the stress exosomes secreted have good anti-inflammatory and antioxidant effects. The inventors packaged the Pichia pastoris stress exosomes with ferulic acid, and unexpectedly found that the Pichia pastoris stress exosomes can not only effectively encapsulate ferulic acid, but also the protein content contained in the Pichia pastoris stress exosomes can be induced to express, which can further increase the encapsulation performance of ferulic acid. At the same time, the Pichia pastoris stress exosomes can also enhance the anti-inflammatory and antioxidant effects of ferulic acid, and can effectively solve the defects of the current ferulic acid encapsulation technology, such as low encapsulation rate, decreased stability, and decreased anti-inflammatory and antioxidant functions.

[0025] In summary, compared with the prior art, the preparation method of the exosome ferulic acid nanocomposite provided by the present invention has the advantages of high safety, low immune rejection, high cell fusion, high encapsulation rate and good stability. In addition, the stress yeast exosomes selected by the present invention can also effectively protect and enhance the anti-inflammatory and antioxidant effects of ferulic acid, so that the prepared exosome ferulic acid nanocomposite has strong anti-inflammatory, antioxidant and repair effects, and the nanocomposite is easy to industrially produce and apply, and has good application prospects in the field of cosmetics or medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is a comparison chart of the repair effects of ferulic acid and Example 2 on NIH-3T3 cells damaged by hydrogen peroxide. DETAILED DESCRIPTION

[0027] The present invention is further described below by the description of specific embodiments, but this is not a limitation of the present invention. Those skilled in the art can make various modifications or improvements based on the basic idea of ​​the present invention, but as long as they do not depart from the basic idea of ​​the present invention, they are all within the scope of the present invention. The materials involved in the present invention are all food grade and can be obtained by commercially available or conventional technical means in the art. For example: The Pichia pastoris was purchased from Beijing Biobo Biotechnology Co., Ltd., the original number is: KM-71, the brand is: Biobo Bio, and the item number is: bio-81782.

[0028] Example 1, Preparation method of exosomes derived from Pichia pastoris:

[0029] Step A, taking the activated Pichia pastoris plate bacteria, inoculating it into a conical flask filled with YEPD culture medium, and culturing it in a shaking incubator at a temperature of 28° C. for 12 h to obtain a Pichia pastoris seed solution;

[0030] Step B, inoculating the Pichia pastoris seed solution prepared in step A into a conical flask filled with fresh YEPD medium, wherein the inoculation amount of the Pichia pastoris seed solution is 5%, and culturing in a shaking incubator at a temperature of 28° C. to mid-logarithmic phase, then raising the temperature in the medium to 40° C., and continuing culturing for 36 hours to reach a stable phase, to obtain a fermentation liquid;

[0031] Step C, centrifuging the fermentation broth obtained in step B at a speed of 6000 rpm for 8 minutes, collecting the supernatant, centrifuging the supernatant at a temperature of 4°C and 6000g for 20 minutes, collecting the supernatant, and filtering the supernatant through a 0.2 μm sterile filter membrane to obtain a filtrate;

[0032] Step D: Centrifuge the filtrate obtained in step C at 120,000 g for 80 min, and discard the supernatant to obtain the product.

[0033] Example 2: A method for preparing exosome ferulic acid nanocomplex

[0034] Step S1. The exosomes derived from Pichia pastoris prepared in Example 1 are added to a phosphate buffered saline solution and resuspended, wherein the concentration of the phosphate buffered saline solution is 0.01 mol / L, and the mass percentage of the exosomes in the suspension is 0.1%, thereby obtaining a yeast-derived exosome solution;

[0035] Step S2. adding ferulic acid to an ethanol solution having a volume concentration of 95%, stirring evenly to make the concentration of ferulic acid 1 mg / mL, and obtaining a ferulic acid solution;

[0036] Step S3. 91% of the yeast-derived exosome solution obtained in step S1 and 9% of the ferulic acid alcohol solution obtained in step S2 were mixed uniformly according to mass percentage to obtain a mixed solution, and the mixed solution was subjected to ultrasonic treatment under ice bath conditions. The conditions of the ultrasonic treatment were: ultrasonic power of 200 W, working time of 5 s, interval time of 10 s, 8 cycles, ice bath cooling for 5 min, ultrasonic treatment again, and then standing at 37 ° C for 60 min, centrifuged at 4 ° C, 8000g for 15 min, and the supernatant was obtained.

[0037] Example 3: A method for preparing exosome ferulic acid nanocomplex

[0038] Step S1. The exosomes derived from Pichia pastoris prepared in Example 1 are added to a phosphate buffered saline solution and resuspended, wherein the concentration of the phosphate buffered saline solution is 0.01 mol / L, and the mass percentage of the exosomes in the suspension is 0.08%, thereby obtaining a yeast-derived exosome solution;

[0039] Step S2. adding ferulic acid to an ethanol solution having a volume concentration of 95%, stirring the mixture to obtain a ferulic acid solution having a concentration of 5 mg / mL;

[0040] Step S3. 95% of the yeast-derived exosome solution obtained in step S1 and 5% of the ferulic acid alcohol solution obtained in step S2 were mixed uniformly according to mass percentage to obtain a mixed solution, and the mixed solution was subjected to ultrasonic treatment under ice bath conditions. The conditions of the ultrasonic treatment were: ultrasonic power of 50 W, working time of 10 s, interval time of 2 s, 40 cycles, ice bath cooling for 10 min, ultrasonic treatment again, and then standing at 25 ° C for 80 min, centrifuging at 8 ° C, 10000g for 10 min, and taking the supernatant to obtain.

[0041] Example 4: A method for preparing exosome ferulic acid nanocomplex

[0042] Step S1. The exosomes derived from Pichia pastoris prepared in Example 1 are added to a phosphate buffered saline solution and resuspended, wherein the concentration of the phosphate buffered saline solution is 0.01 mol / L, and the mass percentage of the exosomes in the suspension is 0.12%, thereby obtaining a yeast-derived exosome solution;

[0043] Step S2. adding ferulic acid to an ethanol solution having a volume concentration of 95%, stirring the mixture to obtain a ferulic acid solution having a concentration of 10 mg / mL;

[0044] Step S3. 84% of the yeast-derived exosome solution obtained in step S1 and 16% of the ferulic acid alcohol solution obtained in step S2 were mixed uniformly according to mass percentage to obtain a mixed solution, and the mixed solution was subjected to ultrasonic treatment under ice bath conditions, and the conditions of the ultrasonic treatment were: ultrasonic power of 400 W, working time of 2 s, interval time of 34 s, 5 cycles, ice bath cooling for 3 min, and ultrasonic treatment again, followed by standing at 20 ° C for 100 min, centrifuging at 2 ° C, 5000g for 10 min, and taking the supernatant to obtain.

[0045] Comparative Example 1: Preparation of Ferulic Acid-β-Cyclodextrin Encapsulation

[0046] Ferulic acid-β-cyclodextrin inclusion complex was prepared by referring to the optimal method of reference (Wang Liping. Preparation of ferulic acid-β-cyclodextrin inclusion complex and study on preservation of hairtail [D]. Zhejiang University, 2018.), that is, ferulic acid aqueous solution and β-cyclodextrin ethanol solution were mixed at a molar ratio of β-cyclodextrin to ferulic acid of 1:0.5, stirred for 24 hours, stored in a refrigerator at 4°C overnight, and then dried in an oven at 60°C for 12 hours.

[0047] Comparative Example 2: Preparation of Ferulic Acid Solid Lipid Nanoparticles

[0048] Ferulic acid solid lipid nanoparticles were prepared according to the method of reference (Gao Yimin, Zhang Zhen, Chen Peimin, et al. Comparison of preparation processes of ferulic acid solid lipid nanoparticles by emulsification volatilization method and thin film-ultrasound method [J]. Food and Fermentation Industries, 2019).

[0049] Comparative Example 3: Preparation of exosome ferulic acid nanocomplex

[0050] Conventional yeast exosomes were prepared according to the method of reference (Yu Qiang. Extraction and characterization of tumor-related cell exosomes and research on their application methods based on aptamers [D]. Beijing: Beijing University of Chemical Technology, 2020.), and the remaining steps were prepared with reference to Example 2 to prepare exosome ferulic acid nanocomplexes.

[0051] Test Example 1: Package Rate Test

[0052] 1. Test materials:

[0053] The exosome ferulic acid nanocomplexes prepared in Examples 2, 3 and 4, the ferulic acid-β-cyclodextrin inclusions prepared in Comparative Example 1, the ferulic acid solid lipid nanoparticles prepared in Comparative Example 2, and the exosome ferulic acid nanocomplexes prepared in Comparative Example 3.

[0054] 2. Test methods:

[0055] Take the exosome ferulic acid nanocomplex prepared in Example 2, Example 3 and Example 4, the ferulic acid-β-cyclodextrin inclusion prepared in Example 1, the ferulic acid solid lipid nanoparticles prepared in Example 2, and the exosome ferulic acid nanocomplex prepared in Example 3 for liquid chromatography analysis; take 10 mg of the sample to be tested, dissolve it in 1 mL of deionized water, ultrasonically dissolve it at room temperature for 10 minutes, and centrifuge it at 8000r / min for 15 minutes, take the supernatant, take 200uL of the supernatant, dissolve it in 2 mL of deionized water, 4°C, 8000g centrifuge for 15 minutes, and take the supernatant for liquid chromatography analysis to determine the content of the encapsulated ferulic acid. Calculate the encapsulation rate according to the following formula:

[0056] Encapsulation rate = encapsulated ferulic acid content / amount of ferulic acid added * 100%

[0057] HPLC analysis was carried out using Shimadzu high performance liquid chromatography, and the detector was SPD-M20; chromatographic conditions: C18 column (4.6mm*150mm; 5μm), detection wavelength: 313nm, column temperature: 35°C, and the mobile phase was methanol-0.1% formic acid water 1mL / min. The conditions were as follows: time program (gradient elution): 0-5min, 10% methanol, 90% formic acid water; 20min, 100% methanol, 0% formic acid water; 20-27min, 100% methanol, 0% formic acid water.

[0058] Preparation of ferulic acid standard solution: accurately weigh 0.0053 g of ferulic acid, dissolve it in methanol and dilute it to a 10 mL volumetric flask to form a mother solution (530 ug / mL), take 0.2, 0.4, 0.8, 1.6, and 3.2 mL respectively, dilute it with methanol and dilute it to a 10 mL volumetric flask to form a series of standard solutions with concentrations of 10.6, 21.2, 42.2, 84.8, and 169.6 ug / mL. Ferulic acid standard curve: y = 46048x + 51151, R 2 =0.9993.

[0059] 3. Test results:

[0060] The test results are shown in Table 1.

[0061] Table 1 Ferulic acid encapsulation rate test results

[0062] Group Packing rate (%) Example 2 89.33 Example 3 83.16 Example 4 80.09 Comparative Example 1 68.82 Comparative Example 2 52.76 Comparative Example 3 73.36

[0063] As can be seen from Table 1, the encapsulation rates of the exosome ferulic acid nanocomposites prepared in Examples 2 to 4 of the present invention are higher than those of Comparative Examples 1, 2 and 3, indicating that the Pichia pastoris stressed exosomes prepared in the present invention are more suitable for encapsulating ferulic acid than β-cyclodextrin, solid lipid nanoparticles and conventional yeast exosomes, have better encapsulation effects, and can effectively improve the stability of ferulic acid.

[0064] Test Example 2: DPPH free radical scavenging ability test

[0065] 1. Test materials:

[0066] Vitamin C, ferulic acid, the exosome ferulic acid nanocomplex prepared in Example 2, and the exosome ferulic acid nanocomplex prepared in Comparative Example 3.

[0067] 2. Test methods:

[0068] DPPH was dissolved in 95% ethanol to prepare a 0.04 mg / mL DPPH solution. Vitamin C, ferulic acid, the exosome ferulic acid nanocomplex prepared in Example 2, and the exosome ferulic acid nanocomplex sample prepared in Comparative Example 3 were prepared into a 1 mg / mL solution and diluted into 5ug / mL and 25ug / mL concentration sample groups (complex concentration in terms of ferulic acid). The sample group was 100uLDPPH mixed with 50uL of each concentration sample group, oscillated evenly, and allowed to stand at room temperature for 30 minutes before measuring the absorbance at 519nm, recorded as A1; the control group was 100uLDPPH mixed with 50uL 95% ethanol, and the absorbance was measured at 519nm, recorded as A0; the blank group was 100uL 95% ethanol mixed with 50uL of each concentration sample group, and the absorbance was measured at 519nm, recorded as A2.

[0069] The DPPH free radical scavenging rate is calculated according to the following formula:

[0070]

[0071] 3. Test results:

[0072] The test results are shown in Table 2.

[0073] Table 2 DPPH free radical scavenging ability test results

[0074]

[0075] As can be seen from Table 2, compared with the ferulic acid group and the comparative example 3 group, the ferulic acid encapsulated by the Pichia pastoris stress exosomes prepared by the present invention can effectively improve the DPPH free radical scavenging rate of the ferulic acid complex. When the ferulic acid concentration is 25 ug / mL, its DPPH free radical scavenging rate is close to that of vitamin C at the same concentration, indicating that the exosome ferulic acid nanocomplex prepared by the present invention has a strong antioxidant effect.

[0076] Test Example 3: Cell Repair Test

[0077] 1. Test materials:

[0078] Ferulic acid (FA), exosome ferulic acid nanocomplex prepared in Example 2.

[0079] 2. Test methods:

[0080] NIH-3T3 cells were cultured using DMEM complete medium (containing 10% fetal bovine serum and 1% double antibody). In a 96-well plate, 100uL NIH-3T3 cell suspension was inoculated in each well at 5000 cells / well. After culturing for 24h, the culture medium was aspirated, the cells were gently washed once with PBS solution, 100uL of 600umoL / mL hydrogen peroxide solution was added for modeling for 2h, and then the hydrogen peroxide solution was aspirated, and the cells were gently washed once with PBS solution. 100uL of the prepared drugs of each concentration (complex concentration was calculated as ferulic acid) was added to the drug administration group (ferulic acid group and Example 2 group), and complete culture medium was added to the model group and the blank control group (containing cells but not modeling). A zeroing group containing only culture medium without cells was set up, and the solution was aspirated after incubation for 48h, and after a gentle wash with PBS, 100uL MTT solution (0.5mg / mL) was added. After 4h, the MTT solution was aspirated, and 150μLDMSO solution was added. After 10min, the OD value was measured at 570nm using an enzyme reader to calculate the relative survival rate of the cells.

[0081] Relative cell survival rate (OD 模型 / 给药 -OD 调零 ) / (OD 阴性对照 -OD 调零 )×100%;

[0082] 3. Test results:

[0083] The test results are as follows Figure 1 As shown. Figure 1 It can be seen that the cell survival rates of ferulic acid and Example 2, as the concentration of ferulic acid increases, the cell survival rate of Example 2 has a significant enhancement effect. When the concentration of ferulic acid is 100ug / mL, the cell survival rate of ferulic acid is 69.06%, and the cell survival rate of Example 2 is 77.84%, and the cell survival rate is increased by 8.84%; when the concentration of ferulic acid is 200ug / mL, the cell survival rate of ferulic acid is 78.45%, and the cell survival rate of Example 2 is 85.90%, and the cell survival rate is increased by 7.45%.

Claims

1. A method for preparing an exosome ferulic acid nanocomposite, characterized in that: The following steps are involved: Step S1. adding yeast-derived exosomes to a phosphate buffered saline solution and resuspending the exosomes so that the mass percentage of the exosomes in the suspension is 0.05-0.12%, thereby obtaining a yeast-derived exosome solution; Step S2. adding ferulic acid to an ethanol solution having a volume concentration of 75 to 95%, stirring uniformly to obtain a ferulic acid solution; Step S3. The yeast-derived exosome solution obtained in step S1 and the ferulic acid alcohol solution obtained in step S2 are mixed evenly to obtain a mixed solution, and the mixed solution is subjected to ultrasonic treatment under ice bath conditions, and then allowed to stand at a temperature of 20 to 37° C. for 60 to 100 minutes, centrifuged, and the supernatant is obtained.

2. The method for preparing the exosome ferulic acid nanocomposite according to claim 1, characterized in that: The method for preparing yeast-derived exosomes in step S1 is: Step A, taking the activated Pichia pastoris plate bacteria, inoculating it into a conical flask filled with YEPD culture medium, and culturing it in a shaking incubator at a temperature of 28° C. for 12 h to obtain a Pichia pastoris seed solution; Step B, inoculating the Pichia pastoris seed liquid prepared in step A into a conical flask filled with fresh YEPD medium at an inoculation amount of 5%, culturing in a shaking incubator at a temperature of 28° C. to the mid-logarithmic phase, then raising the temperature in the medium to 40° C., and continuing to culture for 36 hours to reach a stable phase to obtain a fermentation liquid; Step C, centrifuging the fermentation broth obtained in step B at a speed of 6000-7000 rpm for 8-10 minutes, collecting the supernatant, centrifuging the supernatant at a temperature of 2-8°C and 5000-8000g for 10-30 minutes, collecting the supernatant, and filtering the supernatant through a 0.2 μm sterile filter membrane to obtain a filtrate; Step D: Centrifuge the filtrate obtained in step C at 100,000 to 120,000 g for 60 to 80 min, and discard the supernatant to obtain the product.

3. The method for preparing the exosome ferulic acid nanocomposite according to claim 1, characterized in that: The concentration of the ferulic acid solution in step S2 is 1-10 mg / mL.

4. The method for preparing the exosome ferulic acid nanocomposite according to claim 1, characterized in that: In step S3, the yeast-derived exosome solution and the ferulic acid solution are uniformly mixed in a mass percentage of (80-95):(5-20).

5. The method for preparing the exosome ferulic acid nanocomposite according to claim 1, characterized in that: The conditions of the ultrasonic treatment in step S3 are: under ice bath conditions, the ultrasonic power is 200-400W, the working time is 2-10s, the interval time is 2-34s, the cycle is 5-40 times, and the ice bath is cooled for 3-10min before ultrasonic treatment is performed again.

6. The method for preparing the exosome ferulic acid nanocomposite according to claim 1, characterized in that: The centrifugal conditions in step S3 are: centrifugation at a temperature of 2 to 4° C. and a temperature of 5000 to 10000 g for 10 to 15 min.

7. The exosome ferulic acid nanocomplex prepared by the method for preparing the exosome ferulic acid nanocomplex according to any one of claims 1 to 6.

8. Use of the exosome ferulic acid nanocomplex as claimed in claim 7 in the preparation of cosmetics or medicines.

9. Use of the exosome ferulic acid nanocomplex as claimed in claim 7 in the preparation of repairing antioxidant cosmetics.

Images